S-1/A: First Choice Healthcare Pivots to Primary Care, Seeks $19M IPO

First Choice Healthcare Solutions, Inc. is undergoing a strategic pivot from orthopedic services to a national chain of primary care and wellness clinics, aiming to raise up to $19 million in a public offering.

Summary

• First Choice Healthcare Solutions, Inc. (FCHS) is transitioning its business model from historical orthopedic services to developing a national chain of primary care and wellness clinics.
• The new strategy focuses on providing life improvement services (anti-aging, weight management, hormone replacement) and pharmacy services in high-growth U.S. markets.
• FCHS plans to terminate all remaining legacy orthopedic and physical therapy services upon completion of the offering.
• The company has entered into definitive agreements to acquire Pointe Medical Services, Inc. (including Pointe Med Pharmacy, Livewell MD, LLC, and Livewell Drugstore, LLC) for $15.8 million, payable in cash, debt assumption/payoff, stock, earn-out, and performance bonus.
• FCHS also agreed to acquire the physical and intangible assets of The Good Clinic, Inc. for $3.5 million in an all-stock deal.
• The new corporate structure will include centralized management services under 'Leading Primary Care, Inc.' (proposed new name) with three operating subsidiaries: Live Well Medical Group, The Good Clinic Properties, Inc., and Live Well Drugstore, Inc.
• The public offering aims to raise up to $19,000,000 (or $21,850,000 with over-allotment option exercised) through the sale of 3,800,000 shares of Series D Convertible Preferred Stock and accompanying Warrants at a combined public offering price of $5.00 per share.
• A minimum of $15.0 million must be raised for the public offering to close and for the acquisitions and exchange of notes/liabilities to proceed, with an uplisting to the NYSE planned.
• A 1-for-2,000 reverse stock split of common stock outstanding as of January 30, 2026, will be effected immediately after the registration statement's effectiveness but prior to NYSE listing; this split does not apply to shares issued in the IPO, resale shares, or shares from the acquisitions.
• The acquired compounding pharmacy (LiveWell Drugstore) currently holds licenses in Florida, Georgia, and Mississippi, with plans to expand licensure to all states where clinics operate.
• Pointe Med/Live Well Group (acquired entity) reported net income attributable to shareholders of $1,444,050 for the nine months ended September 30, 2025, an increase from $605,682 for the same period in 2024.
• Pointe Med/Live Well Group's revenue, net of discounts, increased by 19% to $5,107,040 for the nine months ended September 30, 2025, compared to $4,286,015 in 2024.
• Pointe Med/Live Well Group's gross profit margin increased from 83% in 2024 to 85% in 2025 for the nine months ended September 30.
• FCHS itself reported a net loss of $3,500,214 for the nine months ended September 30, 2025, a decrease from $3,954,535 for the same period in 2024.
• FCHS had an accumulated deficit of approximately $71.3 million as of September 30, 2025, and $67.8 million as of December 31, 2024.
• FCHS's cash outflows from operations were approximately $0.55 million for the nine months ended September 30, 2025, and $0.68 million for the same period in 2024.
• The company's ability to continue as a going concern is dependent on successful acquisitions, revenue growth, cost reduction, and securing additional capital.
• Lance Friedman, CEO, holds all 4 outstanding shares of Series A Super Voting Preferred Stock, which will be cancelled upon completion of the offering, eliminating his effective voting control.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company's historical financial performance is poor with a 'going concern' warning, the strategic pivot into high-growth healthcare segments, coupled with the positive performance of the acquired entities and a significant capital raise, presents a potential turnaround. However, the execution risks and reliance on successful capital raise temper the overall sentiment.

Positives

• The strategic pivot to primary care and wellness clinics, including anti-aging, weight management, and hormone replacement, targets high-growth healthcare segments.
• Acquisitions of Pointe Med Pharmacy and The Good Clinic provide established operations and intellectual property for the new strategy.
• The acquired Pointe Med/Live Well Group demonstrated strong financial performance with a 19% revenue increase and a 2 percentage point improvement in gross profit margin for the nine months ended September 30, 2025.
• The new model leverages Nurse Practitioners for primary care, offering an approximate 25% margin improvement over traditional physician-staffed offices due to lower labor costs.
• The internal compounding pharmacy (LiveWell Drugstore) is expected to provide personalized medications at lower costs and attractive margins, with plans for 503B accreditation for broader market access.
• Centralized administrative infrastructure is designed to achieve economies of scale, reducing overhead and fueling income growth as the clinic network expands.
• The company plans to eliminate all unprofitable legacy orthopedic and physical therapy services, focusing resources on the new, higher-potential strategy.
• The planned cancellation of Series A Super Voting Preferred Stock held by the CEO will reduce concentrated voting power, aligning with corporate governance best practices for public companies.

Negatives

• FCHS has a history of significant net losses, with an accumulated deficit of $71.3 million as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• The company has experienced recurring cash outflows from operations, indicating a reliance on external financing.
• The success of the new strategy is contingent on raising at least $15.0 million in the public offering; failure to do so will prevent the closing of acquisitions and debt settlements.
• The new strategy involves significant operational and financial risks, including difficulties in integrating acquisitions, obtaining and maintaining regulatory approvals, and attracting/retaining qualified staff.
• The quality-of-life services, projected to be 15% of clinic revenue, are primarily self-pay, leading to potential revenue volatility, bad debt risks, and pricing challenges.
• The company faces intense competition from well-established virtual and brick-and-mortar healthcare providers, which could impact patient acquisition and profitability.
• The potential for Series D Convertible Preferred Stock anti-dilution provisions to lower the conversion price could result in substantial dilution for common stockholders and depress the stock price.
• The company may not have sufficient authorized shares to satisfy future conversions of Series D Convertible Preferred Stock if the conversion price is significantly reduced, requiring time-consuming and expensive shareholder approval to increase authorized shares.
• The company's former CEO pled guilty to securities fraud, which has tarnished the company's reputation and led to litigation and damage to relationships.

Risks

• Our business has posted minimal profit since commencing operations.
• If our cash from operations is not sufficient to meet our current or future operating needs, expenditures and debt service obligations, our business, financial condition, and results of operations may be materially adversely affected.
• We need additional capital to expand operations; if we do not raise additional capital, we will need to curtail or cease operations.
• Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or other assets.
• Our strategy to open new clinics sites in multiple new markets makes it difficult for us to evaluate our current and future business prospects, and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm our business, financial condition, results of operations and cash flow.
• Changes in tax laws and unanticipated tax liabilities could adversely affect our effective income tax rate and ability to achieve profitability.
• We expect our quarterly financial results to fluctuate.
• Volatility in the financial markets could have a material adverse effect on our business.
• Potential profit margins may decline due to increasing pressure on margins.
• Our indebtedness may have a material adverse effect on our business, financial condition, and results of operations.
• Pandemics and epidemics, including the COVID-19 pandemic, natural disasters, terrorist activities, political unrest, and other outbreaks could have a material adverse impact on our business, results of operations, financial condition and cash flows or liquidity.
• Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of our clinic operations and adversely impact our business.
• We have a limited operating history that impedes our ability to evaluate our potential future performance and strategy.
• Acquisitions involve risks that could adversely affect our business/internal controls.
• If we are unable to attract and retain qualified medical professionals, our ability to maintain operations attract patients or open new primary care clinics could be negatively affected.
• We may have difficulties managing our Company's growth, which could lead to higher operating losses, or we may not grow at all.
• Loss of key executives and failure to attract qualified managers could limit our growth and negatively impact our operations.
• We may be subject to medical professional liability risks, which could be costly and could negatively impact our business and financial results.
• The healthcare regulatory and political framework is evolving.
• The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws or regulations.
• The practice of pharmacy is highly regulated on the state and federal level, and government authorities may determine that we have failed to comply with applicable laws or regulations limiting our opportunity to grow our compounding pharmacy revenue.
• Compounding pharmacies are dependent on the consistent availability and quality of the base pharmaceuticals required to deliver personalized medications to their patients and clinics.
• Federal and state laws that protect the privacy and security of protected health information may increase our costs and limit our ability to collect and use that information and subject us to penalties if we are unable to fully comply with such laws.
• Our primary clinics will be based primarily on the self-pay model, which could lead to lesser patients utilizing our services or the need for us to discount such services, which could limit our growth and negatively impact our operations.
• Changes in the rates or methods of third-party reimbursements for medical services could result in reduced demand for our services or create downward pricing pressure, which would result in a decline in our revenues and harm our financial position.
• We are subject to federal and state restrictions on advertising that may adversely affect our ability to advertise our clinics and services.
• Health Insurance Portability and Accountability Act (HIPAA) compliance is critically important to our continuing operations.
• We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
• The market for healthcare services is highly competitive.
• If we are forced to lower our procedure prices in order to compete with a better-financed or lower-cost provider of medical healthcare services, our medical revenues and results of operations could decline.
• A decline in consumer disposable income could adversely affect the number of clinical visits and could have a negative impact on our financial results.
• We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
• The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are no longer an emerging growth company.
• We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There has been a limited trading market for our Common Stock to date.
• The market for our common stock may fluctuate significantly.
• A significant percentage of the Company's common stock is held by a small number of shareholders.
• The issuance of our common stock in connection with the Company's outstanding convertible preferred stock and warrants could cause substantial dilution, which could materially affect the trading price of our common stock.
• Resales by the selling stockholders under the Resale Prospectus may have an adverse effect on the market price of our Common Stock.
• We have not paid dividends in the past and have no immediate plans to pay dividends.
• We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline.
• Penny stock rules may make buying or selling our securities difficult which may make our stock less liquid and make it harder for investors to buy and sell our securities.
• Our former Chief Executive Officer, Christian C. Romandetti, Sr., was arrested on November 15, 2018, on a conspiracy to commit securities fraud charge.
• Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
• Failure to achieve and maintain internal controls in accordance with Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.

Future Outlook

The company's future outlook is centered on leveraging its two acquisitions (Pointe Med Pharmacy and The Good Clinic) and current administrative infrastructure to build a national system of innovative, branded primary care and wellness clinics. The strategy aims to redefine primary care through personalization, a broad spectrum of services, and internal compounding pharmacy operations. The company expects to commence operations for the primary care and wellness clinics by March 1, 2026, and plans to open a total of thirty new clinics in the next four years, contingent on additional capital. The company anticipates achieving measurable cost and productivity efficiencies through its centralized administrative system and Nurse Practitioner-led care model.

Management Comments

• Management believes the strategy of combining a full suite of primary care services and specialized services with an operational environment focused on high-quality care, excellent customer experience, personalized care plans, and personalized medications has the potential to deliver desired financial performance.
• Management is confident in the market size of the business opportunity, the strength of the strategy, and the experience of the management team.
• Management believes the lower labor costs of employing Nurse Practitioners provide an approximate 25% margin improvement over traditional primary care offices staffed with medical doctors.
• Management believes the centralized system of administrative infrastructure will allow the company to achieve measurable cost and productivity efficiencies as it expands the number of clinics.
• Management believes the scalable structure of administrative back-office functions can efficiently support expansion plans.

Industry Context

StockSavvy.ai notes that First Choice Healthcare Solutions' strategic pivot aligns with broader healthcare trends emphasizing primary care, wellness, and personalized medicine, driven by unsustainable healthcare costs and a demand for more effective, patient-centric models. The focus on Nurse Practitioners for primary care is a growing trend, offering cost efficiencies and potentially improved patient outcomes, as supported by industry studies. The entry into compounding pharmacy services also taps into a niche market for customized medications, differentiating it from traditional primary care providers. However, the market is highly competitive, with established virtual and brick-and-mortar players, requiring significant investment in branding, technology, and regulatory compliance to succeed.

Comparison to Industry Standards

• The company's reliance on Nurse Practitioners for primary care is a competitive strategy, with studies cited from the American Association of Nurse Practitioners, Barnett et al., Stanik-Hutt et al., and Carranza et al. suggesting Nurse Practitioners deliver care equal to or better than physicians, while offering a 25% labor cost advantage over traditional primary care offices staffed with medical doctors.
• The U.S. primary care market is valued at $271.0 billion in 2023 and is expected to grow at a CAGR of 3.36% from 2024 to 2030 (Grand View Research), indicating a significant market opportunity for the company's new strategy.
• The pharmaceutical weight loss market, a segment the company targets, was valued at $6 billion and could grow to $100 billion by 2030 (Goldman Sachs Research), highlighting a high-growth area.
• The Hormone Replacement Therapy (HRT) market, another target, was valued at $6.9 billion in 2022 and is projected to reach $13.4 billion by 2032 (Global Market Insights), showing strong growth potential.
• The U.S. peptides market, relevant to personalized medicine, was valued at $17.8 billion in 2022 and is expected to grow at a CAGR of 7.0% from 2023 to 2030 (Global Market Insights).
• The regenerative medicine US market was estimated at $16.8 billion in 2023 and is projected to grow at a CAGR of 16.72% from 2024 to 2030 (Grand View Research), indicating a rapidly expanding sector.
• The biohacking market, another target, was estimated at $23.9 billion in 2023 and is projected to grow at a CAGR of 19.48% to $67.9 billion by 2032 (Market Research Future), representing a high-growth, niche market.
• Competitors include virtual providers like Hims, Ro, REX MD, Renew Youth, Alloy, Midi, and brick-and-mortar clinics such as Revibe, Herself Health, Oak Street Medical, and One Medical, indicating a fragmented but competitive landscape.

Management Changes

Corporate Governance

Legal Proceedings

• The company's former CEO, Christian C. Romandetti, Sr., pled guilty to conspiracy to commit securities fraud, which led to the company's bankruptcy filing in June 2020.
• The company emerged from Chapter 11 bankruptcy on April 27, 2022, with all litigation settled or converted into unsecured creditors.
• A $1,443,498 liability and lease settlement expense was recorded in October 2021 related to a real estate lease in Melbourne, Florida; approximately $1,200,000 remains unpaid, and the company is working to reach a settlement.
• A $19,473 judgment was granted against the company in January 2024 for an equipment lease, which was subsequently settled for $9,000 in March 2024.
• GMR Melbourne, LLC filed a complaint in September 2021 for breach of contract related to a facilities lease agreement, claiming $1,455,095 in defaulted payments.
• Coastal Neurology, Inc. filed a complaint in May 2023 for breach of contract related to an Escrow Agreement, seeking $100,000 in damages, which was subsequently withdrawn in 2024.
• CBL & Associates Properties, Inc. is seeking $84,051 (including collection costs) for remaining lease payments on a vacated care facility, which is accrued by the company.
• MBABJB Holdings Family Limited Partnership was granted a summary judgment of $102,884 (including attorney fees and costs) in December 2023 for breach of a facilities lease agreement.
• Ackerman, LLP was awarded $548,000 in fees for bankruptcy representation; $203,115 of these legal fees remain unpaid after partial satisfaction of the judgment.
• The company is a defendant in several employment-related matters, primarily due to unpaid wages following staff reductions and terminations, with the majority of cases settled.

Related Party Transactions

• The company's CEO, Lance Friedman, holds all 4 outstanding shares of Series A Super Voting Preferred Stock, which will be cancelled upon completion of the offering.
• Notes payable as of September 30, 2025, include $2,142,105 due to the company's Chief Executive Officer and $151,858 due to the prior Chief Financial Officer, related to deferred compensation, payments to third-party service providers, and other normal course of business items.
• Notes payable as of December 31, 2024, include $1,626,983 due to the CEO, $151,858 due to the prior CFO, and $460,178 due to multiple unrelated parties.
• The company leases space under an operating lease agreement dated October 1, 2019, with Live Well Realty, LLC, a related party, expiring on June 30, 2028.

Stakeholder Impact

• **Shareholders:** Existing common stockholders will experience significant dilution from the reverse stock split and the issuance of new shares in the public offering and acquisitions. The anti-dilution provisions of the Series D Convertible Preferred Stock could lead to further dilution. The cancellation of Super Voting Preferred Stock will increase the relative voting power of common shareholders.
• **Employees:** The strategic pivot involves eliminating legacy orthopedic services, which may lead to further staff reductions in those areas. The new strategy will require hiring key personnel, including Nurse Practitioners, medical, sales, and management professionals for the new primary care and wellness clinics.
• **Customers/Patients:** The company aims to provide a 'more effective medical home' through personalized primary care, wellness services, and an internal compounding pharmacy, potentially offering enhanced patient experience and lower costs. However, the self-pay model for quality-of-life services may limit access for some patients.
• **Suppliers:** The compounding pharmacy's reliance on consistent availability and quality of base pharmaceuticals from licensed wholesalers and API distributors creates supply chain risks. Expansion will require expanding relationships with raw product suppliers.
• **Creditors:** The public offering proceeds are intended to settle certain notes payable and other liabilities, which could improve the company's financial health and ability to meet obligations. However, the 'going concern' warning indicates ongoing risk for creditors if the capital raise is unsuccessful.
• **Regulatory Bodies:** The company's new business model, particularly the compounding pharmacy and multi-state clinic expansion, subjects it to extensive and complex federal and state healthcare regulations (HIPAA, anti-kickback, Stark Law, pharmacy regulations), requiring significant compliance efforts and posing risks of penalties for non-compliance.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and Warrants.
• Uplist common stock to the NYSE under the symbol FCHS (or 'Leading Primary Care, Inc.' after name change).
• Complete the 1-for-2,000 reverse stock split of common stock.
• Finalize the acquisitions of Pointe Medical Services, Inc. and affiliated entities for $15.8 million.
• Finalize the asset acquisition of The Good Clinic, Inc. for $3.5 million.
• Appoint new board members to fill the full Board of Directors.
• Re-establish the Audit, Nominating and Governance, and Compensation Committees in Q3 2025.
• Commence operations for the primary care and wellness clinics as part of the new strategy by March 1, 2026.
• Expand compounding pharmacy state licensures to align with clinic operations.
• Pursue FDA approval for Live Well Drugstore to become an FDA-registered 503B pharmacy.
• Open a total of thirty new clinics in the next four years, contingent on additional capital.

Key Dates

Recommendation

First Choice Healthcare Solutions is undergoing a significant strategic transformation, moving from a historically unprofitable orthopedic business to a primary care and wellness model with integrated pharmacy services. While the company's historical financial performance is weak, marked by recurring losses and a 'going concern' warning, the acquired entities (Pointe Med/Live Well) show positive revenue growth and profitability. The planned public offering and NYSE uplisting are critical for funding this pivot and addressing liquidity issues. However, the success of this new strategy is highly speculative, with substantial execution risks, intense competition, and potential for significant dilution for existing shareholders. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the high-risk, high-reward nature of this turnaround story. Investors should monitor the successful completion of the capital raise, the integration of acquisitions, and the initial performance of the new clinic model before considering further investment.

Keywords

Primary Care, Wellness Clinics, Compounding Pharmacy, Healthcare Solutions, SEC Filing, S-1/A, Public Offering, Convertible Preferred Stock, Warrants, Nurse Practitioners, Anti-aging, Weight Management, Hormone Replacement Therapy, Medical Acquisitions, NYSE Listing, Reverse Stock Split, Going Concern, Healthcare Regulation, HIPAA Compliance, Telehealth